Objective This study sought to evaluate the experiences of individuals who chose to participate in a study and receive prenatal genomic sequencing (pGS) for fetuses with congenital structural anomalies. Method Individuals who received research results of prenatal sequencing were invited to participate in semi‐structured interviews about their experiences. A constructivist grounded theory approach was used to code and analyze interviews. Results Thirty‐three participants from 27 pregnancies were interviewed. Participants were motivated to enroll in the study to find out more about their fetus' condition and prepare for the future. The waiting period was a time of significant anxiety for participants. Most participants felt relief and closure upon receiving results, regardless of the category of result, and had a clear understanding of the implications of the results. Conclusion Participants' experiences with pGS were often intertwined with the experience of having a fetus with an abnormality. Participants were satisfied with the decision to participate in research and the support they received from the healthcare team, although waiting for results was associated with anxiety. The healthcare team plays an integral role in setting expectations and validating feelings of anxiety, fear and uncertainty.

Objective: To evaluate the maternal characteristics associated with consent to a randomized trial of labor induction in pregnancy.Methods: This is a secondary analysis of low-risk nulliparous women randomized to induction of labor at 39 weeks or expectant management. During the trial, the Data and Safety Monitoring Committee requested additional fields on the screening log, which already included race and ethnicity: maternal age, type of insurance, and the reason for declining consent if declined. Results:From August 2016 (start of additional data collection) to August 2017, 1,965 (28%) of the 7,112 eligible women consented to the trial. Consent was more likely for black women (41%, adjusted odds ratio (aOR) 1.47, 95% confidence interval (CI) 1.24-1.74), and less likely for Asian women (15%, aOR 0.64, 95% CI 0.48-0.84), compared with white women (24%). Women without private insurance were more likely to consent (38%, aOR 1.55, 95% CI 1.34-1.79),

Clinical trial registration: Clini caltr ials.gov, www.clini caltr ials.gov, NCT01990612.